CLINICAL AND LABORATORY FEATURES OF NON-ALCOHOLIC FATTY LIVER DISEASE IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE

Derbak M. A., Khramtsova I. O., Koval V. Yu., Lazur Ya. V., Zhovanik N. V

CLINICAL AND EXPERIMENTAL MEDICINE

Scentific article

The article presents the results of studying the clinical and laboratory features of non-alcoholic fatty liver disease in patients with chronic obstructive pulmonary disease (COPD). The study included 142 patients with a confirmed diagnosis of COPD. All patients underwent ultrasound of the abdominal cavity and used a non-invasive method of diagnosis – FibroMax, which includes: FibroTest, ActiTest, SteatoTest, AshTest, NashTest to determine the degree of hepatic steatosis. The study is based on a comprehensive analysis of 10 biochemical parameters: alpha-2-macroglobulin, haptoglobin, Apo-A1, GGTP, total bilirubin, ALT, AST, blood glucose, TG, ZH. Two groups were formed depending on the body weight of patients: 1 group – n=52 patients with COPD with overweight (PMT) and 2 group, n=90 patients with COPD with normal body weight (BMI). According to clinical and laboratory studies, liver dysfunction was found in 35.2% (50/142) of patients with COPD, with a significant predominance of those in the overweight group of 65.4% vs. 17.8% (p <0.05) in patients with normal weight. Dyspeptic complaints were reported by 42.2% of patients with COPD. The patients were complained of bitterness in the mouth, intermittent discomfort in the right hypochondrium and bloating. Asthenovegetative syndrome was found in 83.8% of patients, and also 70.4% had general weakness. Levels of total bilirubin, alkaline phosphatase, gamma-glutamyl-transpeptidase were significantly higher in patients with COPD with BMI compared with patients with BMD (p <0.05), indicating a predominance of cholestasis syndrome. Liver steatosis of 1-2 degrees was registered in 34.6% of patients with COPD. Also, patients with COPD with BMI were found to have elevated levels of total cholesterol and low-density lipoproteins, indicating impaired lipid metabolism in these patients. It should be noted that 25.0% of patients with BMI had only changes in laboratory and instrumental parameters without complaints. It was found that in patients with COPD non-alcoholic fatty liver disease is registered 3.7 times more often in overweight people than in patients with normal body weight and is accompanied by cytolysis and cholestasis syndromes. In every fourth patient with COPD and overweight, there are changes in laboratory and instrumental parameters without complaints, which confirms the frequent latent course of non-alcoholic fatty liver disease at the stage of steatosis.

chronic obstructive pulmonary disease, nonalcoholic fatty liver disease, steatosis, overweight.

1. Nakaz MOZ. Ukraiini vid 27.06.2013 № 555 “Unifikovaniy klinichniy protokol pervinnoyi, vtorinnoyi (spetsializovanoyi), tretinnoyi (visokospetsializovannoyi) medichnoyi dopomogi ta medichnoyi reabilitatsiyi, “Hronichne obstruktivne zahvoryuvannya legen”. Chinniy vid 2013-06-27. Ministerstvo Ohoroni Zdorovya Ukrayini. Kyiv 2013 [cited 2013 cherven’23]; 100 s. Dostupno: https://www.dec.gov.ua/ wp-content/uploads/2019/ 11/2013_555hozl_ykpmd.pdf [in Ukrainian].
2. Global Initiative for Chronic Obstructive Lung Disease (GOLD): Update Feb. 2015. Available from: http://www.goldcopd.org
3. Stepanov YuM, Nedzvetska NV, Yagmur VB, Klenina IA. Nealkogolna zhirova hvoroba pechInki: osoblivosti metabolichnih zmin na riznih etapahrozvitku hvorobi. GastroenterologIya. 2018;52(1):1-6. [in Ukrainian].
4. Vdovichenko VI, AksentIychuk HB. Poshirenist nealkogolnoyi zhirovoyi hvorobi pechinki sered pomerlih, yaki strazhdali na tsukroviy diabet 2 tipu. Suchasna gastroenterologiya. 2013;1(69):41-6. [in Ukrainian].
5. Stepanov YuM, Filippova OYu. Steatoz i steatogepatit – trigeri pechinkovogo fibrogenezu? Gastroenterologiya. 2013;2(48):97-106. [in Ukrainian].
6. Tereschenko YuA, Tereschenko SYu. Bessimptomnoe povyishenie aktivnosti syivorotochnyih aminotransferaz: etapyi diagnosticheskogo poiska. Rossiyskiy zhurnal gastroenterologii, gepatologii, koloproktologii. 2014;24(1):29-38. [in Russian].
7. Kolomoets MYu, Vashenyak OO. Komorbidnist i polimorbidnist u terapevtichniy praktitsi. Ukrayinskiy medichniy chasopis. 2012;5(91) IX/X:140-1. Dostupno: www.umj.com.ua [in Ukrainian].
8. Mostoviy YuM. Hronichne obstruktivne zahvoryuvannya legen. Klyuchovi pitannya. Ukr. med. chasopis. 2016;4:63-6. [in Ukrainian].
9. Bhatt SP, Dransfield MT. AECOPD: Acute exacerbations of chronic obstructive cardiopulmonary disease? Am. J. Respir. Crit. Care Med. 2013 Nov 1;188(9):1046-8.
10. Gashinova KYu. Sistemni efekti i komorbidnist u ambulatornih patsientiv z HOZL. Ukr. pulmonol. zhurnal. 2013;2:41-5. [in Ukrainian].
11. Fediv OI, Tsintar TP, Ushakov VI. Tsitokinoviy profil i vmist adipokiniv u hvorih na nealkogolniy steatogepatit, poednaniy iz hronichnim obstruktivnim zahvoryuvannyam legen. Bukovinskiy medichniy visnik. 2017;21(3):108-13. Dostupno: http://nbuv.gov.ua/UJRN/ bumv_2017_21_3_18 [in Ukrainian]. 2017; 21 (3):108-113.
12. Samuleeva YuV, Zadionchenko VS, Li VV, Adasheva TV, Samorukova EI, Pihlak AE, i dr. Ozhirenie i metabolicheskie narusheniya u bolnyih hronicheskoy obstruktivnoy boleznyu legkih: vozmozhnosti fenotipirovaniya. Pulmonologiya. 2015;5:32-8. [in Russian].
13. Waschki B, Kirsten AM, Holz O, Meyer T, Lichtinghagen R, Rabe KF, et al. Angiopoietin-like protein 4 and cardiovascular function in COPD. BMJ Open Respir Res. 2016;3(1):7. DOI: 10.1136/bmjresp-2016-000161
14. Bichkova SA. Kliniko-funktsionalni osoblivosti perebigu hronichnogo obstruktivnogo zahvoryuvannya legen, poednanogo z metabolichnim sindromom. Likarska sprava. 2014;7-8:54-9. [in Ukrainian].
15. Kumor Kisielewska A, Kierszniewska Stepien D, Pietras T, Kroczynska Bednarek J, Kurmanowska Z, Antczak A, et al. Assessment of leptin and resistin levels in patients with chronic obstructive pulmonary. Pol Arch Med Wewn. 2013;123:215-20. DOI: 10.20452/ pamw.1724
16. Ostrovskiy MM, Korzh NV. Markeri sistemnogo zapalennya ta nadmirna masa tila u hvorih na hronIchne obstruktivne zahvoryuvannya legen iz III stupenem bronhoobstruktsiyi. Astma ta AlergIya. 2019;2:10-6. [in Ukrainian].
17. Treumova SI, Petrov EE, Boryak VP. Hronichne obstruktivne zahvoryuvannya legen u poednannI z metabolichnim sindromom. Visnik problem biologiyi i meditsini. 2015;1:33-6. [in Ukrainian].
18. Vanfleteren LEGW, Lamprecht B, Studnicka M, Kaiser B, Gnatiuc L, Burney P, et al. Body mass index and chronic airflow limitation in a worldwide population-based study. Chron Respir Dis. 2016;13(2):90-101. DOI: 10.1177/1479972315626012
19. Vujic T, Nagorni O, Maric G, Popovic L, Jankovic J. Metabolic syndrome in patients with chronic obstructive pulmonary disease: frequency and relationship with systemic inflammation. Hippokratia. 2016;20(2):110-4.
20. Mostovoy YuM, Rasputina LV, Dovgan AO. Problema komorbidnih staniv u natsionalniy ugodi z diagnostiki ta likuvannya hronichnogo obstruktivnogo zahvoryuvannya legen iz pozitsiyi vlasnogo dosvidu. Obgovorennya Nakazu № 555. Buk. med. visnik. 2014;18(3):221-6. [in Ukrainian].

«Bulletin of problems biology and medicine» Issue 4 (158), 2020 year, 122-125 pages, index UDK 616.36-004:616.24-002

10.29254/2077-4214-2020-4-158-122-125